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Effectiveness of inﬂuenza vaccine in elderly people
with chronic pulmonary and cardiovascular diseases in
Argentina
F. Nacinovich1, P. Bonvehi2,∗, R. Ruttimann1, D.
Stamboulian3
1 FUNCEI, Buenos Aires, Argentina
2 CEMIC, BUENOS AIRES, Argentina
3 FUNCEI; Clinical Director, Ciudad Autonoma de Buenos
Aires, Argentina
Background: Inﬂuenza immunization proved to be effec-
tive in decreasing pneumonia hospitalizations in the elderly
and in patients with high-risk conditions. The purpose of this
study was to assess the effectiveness of inﬂuenza vaccine in
persons + 65 years with chronic pulmonary and cardiovascu-
lar diseases during four immunization campaign seasons in
Argentina.
Methods: Inﬂuenza vaccines containing the strains specif-
ically recommended by the WHO were administered free of
charge in immunization campaigns from 1994 to 1999. Dur-
ing campaigns, demographic data and disease status of each
subject who was immunized was obtained through interview
before vaccine was administered. Subjects with chronic
pulmonary (CPD) and cardiovascular disease (CVD) were ret-
rospectively evaluated for hospitalization due to pneumonia
during the previous inﬂuenza season (June-October;1995-
1998) and vaccination status.
Results: A total of 176.778 people with CVD and 82.385
with CPD were evaluated. Annual inﬂuenza vaccine effec-
tiveness for reduction of pneumonia hospitalization was:
1995%
(95%CI)
1996%
(95%CI)
1997%
(95%CI)
1998%
(95%CI)
CVD 43 (33-52) 36 (28-46) 29 (18-38) 37 (26-46)
CPD 41 (32-48) 35 (27-41) 27 (19-35) 27 (18-35)
Conclusion: Inﬂuenza vaccination is associated with a sig-
niﬁcant reduction in hospitalization rates due to community
acquired pneumonia in the elderly population in Argentina,
particularly in those with high-risk conditions. Widespread
use of inﬂuenza vaccine should be promoted.
doi:10.1016/j.ijid.2010.02.624
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Development and immunogenicity of a novel polyetherim-
ine (PETIM) dendrimer based nanoformulated DNA rabies
vaccine
M. Shampur1,∗, U. Padinjarenmattathil 2, A. Desai 3, J.
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1 National Institute of Mental health and Neurosciences
(NIMHANS), 560029, India
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3 National Institute Of Mental health & Neurosciences, Ban-
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4 Indian Institute of Science, Bangalore, India
Background: Rabies is a fatal but preventable. In the past
decade attempts have been made to develop an effective
K
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NA vaccine against rabies. However, the effectiveness of
lasmid DNA vaccines is limited due to ineffective intracel-
ular gene delivery. Recently, a group of compounds called
endrimers have been shown to mediate effective gene
elivery. In this study we have developed a novel, polether-
mine (PETIM) dendrimer-based nano-formulated plasmid
NA rabies vaccine and evaluated its immunogenicity.
Methods: The full length glycoprotein gene of rabies
irus was cloned into the expression vector pIRES and its
xpression veriﬁed. Fourth generation amine-terminated
olyetherimine (PETIM) dendrimer was synthesized and
haracterized. PETIM-pDNA complexes were prepared at
arying ratios and their size, shape, transfection efﬁ-
iency and cytotoxicity were studied. In vitro transfection
xperiments were conducted to identify the formulation
ossessing maximal transfection ability. The ability of the
endrimer to protect the encapsulated DNA was studied by
eoxyribonuclease protection assay. The in vivo efﬁcacy of
he dendrimer-DNA complexes was evaluated by studying
he virus neutralizing antibody responses in Swiss albino
ice immunized with these formulations, in comparison
ith those produced by unmodiﬁed plasmid DNA.
Results: The PETIM dendrimer was found to be non-
oxic to cultured mammalian cells upto 1mg/mL. It was
lso observed to protect the complexed DNA from nuclease
egradation. The PETIM-DNA complexes were also observed
o produce satisfactory expression of the encoded gene in
ransfected cells. The animals immunized intramuscularly
ith the dendrimeric formulations of plasmid DNA produced
dequate titres of protective, rabies-virus neutralizing anti-
odies by 2 weeks post-vaccination, after a single dose.
he mean titre of neutralizing antibody was higher (1:512)
n mice immunized with the dendrimeric formulations than
n the group immunized with the unmodiﬁed plasmid DNA
1:16) (p < 0.05).
Conclusion: The fourth generation polyetherimine den-
rimer is a promising nano-carrier for plasmid DNA rabies
accines. Its utility in immunization of larger animals and
umans needs to be evaluated further.
oi:10.1016/j.ijid.2010.02.625
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Background: Among the top ten causes of poor health in
he district are complications due to vaccine preventable
iseases notably diphtheria, pertussis and tetanus (DPT). In
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008, the DPT dropout rate in Kabarole was high (18%). This
tudy assessed the service, community and individual factors
ssociated with DPT1-3 dropout in Kabarole District.
Methods: A cross sectional study using cluster sampling
as employed. Two clusters at parish level (rural and urban)
ach from a county in the district were selected by sim-
le random sampling and all villages therein were studied.
total of 230 children (115 from either cluster) were
ecruited and their parent or guardian interviewed. Cross-
abulations and chi-square tests were used to determine the
trength of associations between independent variables and
he outcome. Binary logistic regression was done to adjust
or potential confounders and identify independent predic-
ors. Key informant interviews were held with in-charges of
ealth units. Qualitative data was analysed manually using
hematic approach and results presented in the form of text.
Results: Factors found to be associated with DPT1-3
ropout were; lack of caretaker knowledge about DPT
osage, (adj. OR = 8.2; 95% CI: 3.12, 21.53); Child’s Birth
rder, 6th and above (adj. OR = 3.0; 95% CI: 0.80, 11.05);
hild Birth Order 2-3 (adj. OR = 2.2; 95% CI: 0.70, 6.71);
hild age group 31-36 compared to 12-18 (adj. OR = 2.5; 95%
I: 0.81, 7.84). However, Rural residence (OR = 1.2; 95% CI:
.56, 2.57); and Child without immunisation card (OR = 4.4;
5% CI: 0.35, 39.86) were not signiﬁcantly associated with
PT dropout.
Conclusion: The current DPT1-3 dropout prevalence in
abarole is still high but dropping (13.7%). DPT 1-3 dropout
s associated with caretaker lack of knowledge of number of
osages a child should receive and involvement of religious
eaders, long travel distance to point of accessing trans-
ort means, and convenient time for immunisation. Findings
rom this study can be used to improve DPT immunisation
ervices. Speciﬁc campaigns on DPT immunisation through
ome visits, involving community leaders and full day immu-
isation can help further reduce the dropout rate.
oi:10.1016/j.ijid.2010.02.626
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ntibody persistence 10 years after 1st and 2nd doses of
3-valent pneumococcal polysaccharide vaccine (PN23),
nd immunogenicity and safety of 2nd and 3rd doses in
lder adults
. Manoff1,∗, R. McFetridge1, C. Liss1, R. Marchese1, J.
abb2, A. Rueda3, D. Musher3
Merck, North Wales, PA, USA
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on, TX, USA
Background: In a clinical trial in ambulatory older adults,
st and 2nd PN23 doses induced signiﬁcant increases in IgG
ntibody and were generally well tolerated. We re-enrolled
rial participants to study 10-year antibody persistence fol-
owing the earlier doses, and immunogenicity and safety of
nd or 3rd PN23 doses.Methods: Ten years after receiving a 1st or 2nd PN23
ose, 143 trial participants (age 60-93 years, median 77)
ere re-enrolled and revaccinated (2nd dose n = 72, 3rd dose
= 71). Sera obtained before and 30 days postvaccination
r
l
t
aternational Congress on Infectious Diseases (ICID) Abstracts
ere analyzed by ELISA for IgG to vaccine serotypes 3, 4,
B, 8, 9 V, 12F, 14, and 23F. Participants recorded all adverse
xperiences (AEs) through 14 days postvaccination. Serious
Es were monitored through 30 days postvaccination.
Results: Ten years postvaccination, geometric mean con-
entrations (GMCs) in 1st- and 2nddose recipients remained
igher than prevaccination GMCs in 1st-dose subjects (when
hey were vaccine-naive) for all but serotype 3. Second
nd 3rd doses induced signiﬁcant increases in GMCs for
and 6 serotypes, respectively; GMCs for all 8 serotypes
ncreased in participants < and ‘‘75 years old. Frequencies
f injection-site and systemic AEs were lower after the 2nd
han the 3rd dose. Among 3rd-dose recipients, injection-site
ain, swelling, and redness were reported by 75%, 39%, and
0%, respectively, while fatigue, body aches, and headache
ere reported by 38%, 34%, and 25%, respectively. Fever
oral temperature ‘‘100 ◦F [37.8 ◦C]) occurred in 0% and 6%
f 2nd- and 3rd-dose recipients, respectively; the maxi-
um reported temperature was 100.2 ◦F (37.9 ◦C). AEs after
ither dose were generally mild, and > 90% resolved within
week. No vaccine-related serious AEs were reported.
Conclusion: Although protective levels have not been
stablished for adults, antipneumococcal antibody is known
o protect against pneumococcal disease. In ambulatory
lder adults, 1st and 2nd PN23 doses induced IgG antibody to
accine serotypes which still exceeded vaccine-naive levels
fter 10 years. Moreover, 2nd and 3rd doses administered 10
ears after the previous dose were immunogenic and gen-
rally well tolerated in those < and ‘‘75 years old. These
ndings are consistent with a beneﬁcial effect of 1st, 2nd,
nd 3rd PN23 doses.
oi:10.1016/j.ijid.2010.02.627
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Background: Argentine has been polio free since 1984 and
as a sustained and active surveillance of the acute ﬂaccid
aralysis (AFP) that involves an epidemiology and laboratory
pproach, reaching all the PAHO indicators. In this context
e describe the emergence of a case of AFP due to an VDPV
n a 15-months old boy with polyclonal agammaglobuline-
ia.
Methods: The case was notiﬁed to the National Program,
nd a stool sample and a throat swab were sent to the
egional Reference Center for Polio Diagnosis. Samples were
noculated in Rd and L20B cells following the new algorithm
ecommended by WHO. In less than 2 days a virus was iso-
ated in both samples which were characterized as a polio
ype 1. They were sequenced in the VP1 region, 5ˇıNCR. As
result we found a 3,7% (stool sample) and 3,5% (throat
